Abstract
Despite recent advancements in the treatment of cancer, the prognosis for patients with malignant brain tumors remains poor. The success of currently available therapies has been limited in part because of the disseminated nature of these tumors. Furthermore, most of these tumors, when in a high-grade form, are resistant to chemo- and radiotherapy. Taking the above considerations into account, effective treatment of these cancers not only requires the development of new means to target tumor burdens that have dispersed significantly from their site of origin, but also therapeutic approaches which can appropriately discriminate between tumor cell and normal brain. In the past two decades, novel approaches involving the use of oncolytic adenoviruses to target malignant brain tumors have undergone extensive investigation and proven to be an effective mode of antiglioma therapy. While the use of various oncolytic adenoviruses has been proven to be safe for local delivery in preclinical and clinical trials, the successful application of this approach in the clinic has been hampered by the host immune response against the viral vector. The discovery of the inherent tumor-tropic properties of neural stem cells (NSCs) provides a unique opportunity that employs NSCs as a cellular vehicle to track tumor cells and deliver therapeutic oncolytic virus. This presents a novel platform for targeted delivery of oncolytic adenovirus to disseminated tumors selectively while hiding the therapeutic virus from the host immune system. NSC loaded with an oncolytic adenovirus offer a more selective and effective method of targeting satellite tumor burdens and this chapter reviews the methodology associated with this unique approach.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer, Cell 100, 57–70.
Kelly, E., and Russell, S. J. (2007) History of oncolytic viruses: genesis to genetic engineering, Mol Ther 15, 651–659.
Guo, Z. S., Thorne, S. H., and Bartlett, D. L. (2008) Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses, Biochimica et biophysica acta 1785, 217–231.
Lesniak, M. S. (2007) Advances in neuro-oncology: novel therapies and clinical trials, Expert review of anticancer therapy 7, S1.
Lesniak, M. S. (2005) Brain tumors: controversies and challenges in management, Expert review of neurotherapeutics 5, 1–2.
Lesniak, M. S. (2006) Gene therapy for malignant glioma, Expert review of neurotherapeutics 6, 479–488.
Parker, J. N., Bauer, D. F., Cody, J. J., and Markert, J. M. (2009) Oncolytic viral therapy of malignant glioma, Neurotherapeutics 6, 558–569.
Fisher, K. (2006) Striking out at disseminated metastases: the systemic delivery of oncolytic viruses, Current opinion in molecular therapeutics 8, 301–313.
Brustle, O., Spiro, A. C., Karram, K., Choudhary, K., Okabe, S., and McKay, R. D. (1997) In vitro-generated neural precursors participate in mammalian brain development, Proceedings of the National Academy of Sciences of the United States of America 94, 14809–14814.
Aboody, K. S., Brown, A., Rainov, N. G., Bower, K. A., Liu, S., Yang, W., Small, J. E., Herrlinger, U., Ourednik, V., Black, P. M., Breakefield, X. O., and Snyder, E. Y. (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas, Proceedings of the National Academy of Sciences of the United States of America 97, 12846–12851.
Benedetti, S., Pirola, B., Pollo, B., Magrassi, L., Bruzzone, M. G., Rigamonti, D., Galli, R., Selleri, S., Di Meco, F., De Fraja, C., Vescovi, A., Cattaneo, E., and Finocchiaro, G. (2000) Gene therapy of experimental brain tumors using neural progenitor cells, Nature medicine 6, 447–450.
Tyler, M. A., Ulasov, I. V., Sonabend, A. M., Nandi, S., Han, Y., Marler, S., Roth, J., and Lesniak, M. S. (2009) Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo, Gene therapy 16, 262–278.
Aboody, K. S., Najbauer, J., and Danks, M. K. (2008) Stem and progenitor cell-mediated tumor selective gene therapy, Gene therapy 15, 739–752.
Coukos, G., Makrigiannakis, A., Kang, E. H., Caparelli, D., Benjamin, I., Kaiser, L. R., Rubin, S. C., Albelda, S. M., and Molnar-Kimber, K. L. (1999) Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer, Clin Cancer Res 5, 1523–1537.
Bewig, B., and Schmidt, W. E. (2000) Accelerated titering of adenoviruses, BioTechniques 28, 870–873.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Ahmed, A.U., Ulasov, I.V., Mercer, R.W., Lesniak, M.S. (2012). Maintaining and Loading Neural Stem Cells for Delivery of Oncolytic Adenovirus to Brain Tumors. In: Kirn, D., Liu, TC., Thorne, S. (eds) Oncolytic Viruses. Methods in Molecular Biology, vol 797. Humana, Totowa, NJ. https://doi.org/10.1007/978-1-61779-340-0_8
Download citation
DOI: https://doi.org/10.1007/978-1-61779-340-0_8
Published:
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-1-61779-339-4
Online ISBN: 978-1-61779-340-0
eBook Packages: Springer Protocols